Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sarepta (SRPT) SRP-4053 Data Provides 'Strong Validation' - SunTrust
September 6, 2017 11:54 AM EDTSunTrust Robinson Humphrey analyst Edward Nash reiterated a Buy rating and $56 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive muscle biopsy results from the Phase I/II 4053-101 study that evaluated golodirsen (SRP-4053) for the treatment of DMD patients... More
Sarepta (SRPT) Could See Exon 53 Approval in 2018, Peak Sales of ~$800M - William Blair
September 6, 2017 11:06 AM EDTWilliam Blair analyst Tim Lugo weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive interim 48-week data from its ongoing European Phase I/II study for DMD patients amenable to skipping exon 53 with golodirsen (SRP-4053).
Lugo notes all... More
UPDATE: Sarepta Therapeutics (SRPT) PT Raised to $55 at Piper Jaffray
September 6, 2017 10:57 AM EDT(Updated - September 6, 2017 11:00 AM EDT)
(updated to add analyst comment)
Piper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $55.00 (from $50.00) while maintaining a Overweight rating.
Analyst Edward Tenthoff notes the positive Exon 53 data. The analyst further comments... More
